PECULIARITIES OF ALTERNATIVE FUEL AND POWER POTENTIAL WITHIN AVIATION TRANSPORT LAND MANAGEMENT DEVELOPMENT

The article analyses peculiarities and specific features of the use of alternative power and fuel capacities during its formation in the sphere of air transport land management. The following elements of the system for producing power-efficient resources comprises have been considered. It substantiates the necessity to involve the concepts of design and use of a modern power-efficient airport infrastructure and its connection with sound and efficient land management. The authors consider the experience of other countries and the perspectives of alternative power and fuel resources – the "green areas". Also It have been established that every new project of an airport or a reconstructed one, shall be focused on meeting the latest standards of minimization of the airport’s impact on the environment and on the reduction of climatic changes, connected with its infrastructure and activities. Within the studies of the experts in the sphere of the aviation industry, and the members of ICAO council, it have been considered the concept of development and use of a modern, power-efficient airport infrastructure. The authors have proposed a modification of the methodological calculation of resource conservation indicators by reducing fossil fuel emissions within the airport and surrounding areas.The article analyses peculiarities and specific features of the use of alternative power and fuel capacities during its formation in the sphere of air transport land management. The following elements of the system for producing power-efficient resources comprises have been considered. It substantiates the necessity to involve the concepts of design and use of a modern power-efficient airport infrastructure and its connection with sound and efficient land management. The authors consider the experience of other countries and the perspectives of alternative power and fuel resources – the "green areas". Also It have been established that every new project of an airport or a reconstructed one, shall be focused on meeting the latest standards of minimization of the airport’s impact on the environment and on the reduction of climatic changes, connected with its infrastructure and activities. Within the studies of the experts in the sphere of the aviation industry, and the members of ICAO council, it have been considered the concept of development and use of a modern, power-efficient airport infrastructure. The authors have proposed a modification of the methodological calculation of resource conservation indicators by reducing fossil fuel emissions within the airport and surrounding areas

Smart Portable Fluorometer for Express-Diagnostics of Photosynthesis: Principles of Operation and Results of Experimental Researches

In the Institute of Cybernetics of National Academy of Sciences of Ukraine the smart portable fluorometer for express-diagnostics of photosynthesis was designed. The device allows easy to estimate the level of influence of natural environment and pollutions to alive plants. The device is based on real time processing of the curve of chlorophyll fluorescent induction. The principles of operation and results of experimental researches of device are described in the article

Smart Portable Tester for Bird Flue Express-Diagnostics: Principles of Design

In the V.M. Glushov Institute of Cybernetics of National Academy of Sciences of Ukraine in collaboration with O.V. Palladin’s Institute of Biochemistry of National Academy of Sciences of Ukraine the smart portable device for express-diagnostics of acute viral infections, including bird flu, is designed. The device is based on the effect of surface plasmon resonance. The principles of device are described in the article

Життя всеціло віддане науці, людям та улюбленій справі (до 80-річчя з дня народження Тарасенко Лідії Мусіївни)

7 листопада 2017 року виповнилось би 80 років відомому вченому в галузі фізіології і патофізіології екстремальних станів, дійсному члену Нью-Йоркської Академії наук, відміннику охорони здоров'я України, відміннику вищої школи України, доктору медичних наук, професору Лідії Мусіївні Тарасенко. Висока кваліфікація та наукова ерудиція Лідії Мусіївни дозволили їй виконати чимало фундаментальних досліджень, результати яких мають велике теоретичне та практичне значення. Предметом наукового пошуку Тарасенко Л.М. була проблема стресу, вивченню якої вона присвятила майже 50 років. Наукові пріоритети Л.М. Тарасенко стосувались вивчення молекулярних механізмів стресорного ушкодження органів та тканин. Під її керівництвом виконано 16 дисертацій: 3 докторських (проф. Петрушанко Т.О., проф. Скрипник І.М., проф. Непорада К.С.) та 13 кандидатських. Тарасенко Л.М. була постійним науковим консультантом викладачів клінічних кафедр. Тарасенко Л.М. була членом Міжнародного патофізіологічного, Українського патофізіологічного та біохімічного товариств, членом спеціалізованих вчених рад по захисту докторських дисертацій у ВДНЗУ «Українська медична стоматологічна академія» (м. Полтава) та Харківському національному медичному університеті. Ім’я Лідії Мусіївни Тарасенко назавжди залишиться в історії вітчизняної медичної науки, в серцях її учнів і тих, хто особисто знав чи вчився на її наукових працях

Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD

BACKGROUND Treatment guidelines recommend the use of inhaled long-acting bronchodilators to alleviate symptoms and reduce the risk of exacerbations in patients with moderate-tovery-severe chronic obstructive pulmonary disease (COPD) but do not specify whether a long-acting anticholinergic drug or a β2-agonist is the preferred agent. We investigated whether the anticholinergic drug tiotropium is superior to the β2-agonist salmeterol in preventing exacerbations of COPD. METHODS In a 1-year, randomized, double-blind, double-dummy, parallel-group trial, we compared the effect of treatment with 18 μg of tiotropium once daily with that of 50 μg of salmeterol twice daily on the incidence of moderate or severe exacerbations in patients with moderate-to-very-severe COPD and a history of exacerbations in the preceding year. RESULTS A total of 7376 patients were randomly assigned to and treated with tiotropium (3707 patients) or salmeterol (3669 patients). Tiotropium, as compared with salmeterol, increased the time to the first exacerbation (187 days vs. 145 days), with a 17% reduction in risk (hazard ratio, 0.83; 95% confidence interval [CI], 0.77 to 0.90; P<0.001). Tiotropium also increased the time to the first severe exacerbation (hazard ratio, 0.72; 95% CI, 0.61 to 0.85; P<0.001), reduced the annual number of moderate or severe exacerbations (0.64 vs. 0.72; rate ratio, 0.89; 95% CI, 0.83 to 0.96; P=0.002), and reduced the annual number of severe exacerbations (0.09 vs. 0.13; rate ratio, 0.73; 95% CI, 0.66 to 0.82; P<0.001). Overall, the incidence of serious adverse events and of adverse events leading to the discontinuation of treatment was similar in the two study groups. There were 64 deaths (1.7%) in the tiotropium group and 78 (2.1%) in the salmeterol group. CONCLUSIONS These results show that, in patients with moderate-to-very-severe COPD, tiotropium is more effective than salmeterol in preventing exacerbations. (Funded by Boehringer Ingelheim and Pfizer; ClinicalTrials.gov number, NCT00563381.

Multiple Myeloma Treatment in Real-world Clinical Practice : Results of a Prospective, Multinational, Noninterventional Study

Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: M.M. has received personal fees from Janssen, Celgene, Amgen, Bristol-Myers Squibb, Sanofi, Novartis, and Takeda and grants from Janssen and Sanofi during the conduct of the study. E.T. has received grants from Janssen and personal fees from Janssen and Takeda during the conduct of the study, and grants from Amgen, Celgene/Genesis, personal fees from Amgen, Celgene/Genesis, Bristol-Myers Squibb, Novartis, and Glaxo-Smith Kline outside the submitted work. M.V.M. has received personal fees from Janssen, Celgene, Amgen, and Takeda outside the submitted work. M.C. reports honoraria from Janssen, outside the submitted work. M. B. reports grants from Janssen Cilag during the conduct of the study. M.D. has received honoraria for participation on advisory boards for Janssen, Celgene, Takeda, Amgen, and Novartis. H.S. has received honoraria from Janssen-Cilag, Celgene, Amgen, Bristol-Myers Squibb, Novartis, and Takeda outside the submitted work. V.P. reports personal fees from Janssen during the conduct of the study and grants, personal fees, and nonfinancial support from Amgen, grants and personal fees from Sanofi, and personal fees from Takeda outside the submitted work. W.W. has received personal fees and grants from Amgen, Celgene, Novartis, Roche, Takeda, Gilead, and Janssen and nonfinancial support from Roche outside the submitted work. J.S. reports grants and nonfinancial support from Janssen Pharmaceutical during the conduct of the study. V.L. reports funding from Janssen Global Services LLC during the conduct of the study and study support from Janssen-Cilag and Pharmion outside the submitted work. A.P. reports employment and shareholding of Janssen (Johnson & Johnson) during the conduct of the study. C.C. reports employment at Janssen-Cilag during the conduct of the study. C.F. reports employment at Janssen Research and Development during the conduct of the study. F.T.B. reports employment at Janssen-Cilag during the conduct of the study. The remaining authors have stated that they have no conflicts of interest. Publisher Copyright: © 2018 The AuthorsMultiple myeloma (MM) remains an incurable disease, with little information available on its management in real-world clinical practice. The results of the present prospective, noninterventional observational study revealed great diversity in the treatment regimens used to treat MM. Our results also provide data to inform health economic, pharmacoepidemiologic, and outcomes research, providing a framework for the design of protocols to improve the outcomes of patients with MM. Background: The present prospective, multinational, noninterventional study aimed to document and describe real-world treatment regimens and disease progression in multiple myeloma (MM) patients. Patients and Methods: Adult patients initiating any new MM therapy from October 2010 to October 2012 were eligible. A multistage patient/site recruitment model was applied to minimize the selection bias; enrollment was stratified by country, region, and practice type. The patient medical and disease features, treatment history, and remission status were recorded at baseline, and prospective data on treatment, efficacy, and safety were collected electronically every 3 months. Results: A total of 2358 patients were enrolled. Of these patients, 775 and 1583 did and did not undergo stem cell transplantation (SCT) at any time during treatment, respectively. Of the patients in the SCT and non-SCT groups, 49%, 21%, 14%, and 15% and 57%, 20%, 12% and 10% were enrolled at treatment line 1, 2, 3, and ≥ 4, respectively. In the SCT and non-SCT groups, 45% and 54% of the patients had received bortezomib-based therapy without thalidomide/lenalidomide, 12% and 18% had received thalidomide/lenalidomide-based therapy without bortezomib, and 30% and 4% had received bortezomib plus thalidomide/lenalidomide-based therapy as frontline treatment, respectively. The corresponding proportions of SCT and non-SCT patients in lines 2, 3, and ≥ 4 were 45% and 37%, 30% and 37%, and 12% and 3%, 33% and 27%, 35% and 32%, and 8% and 2%, and 27% and 27%, 27% and 23%, and 6% and 4%, respectively. In the SCT and non-SCT patients, the overall response rate was 86% to 97% and 64% to 85% in line 1, 74% to 78% and 59% to 68% in line 2, 55% to 83% and 48% to 60% in line 3, and 49% to 65% and 36% and 45% in line 4, respectively, for regimens that included bortezomib and/or thalidomide/lenalidomide. Conclusion: The results of our prospective study have revealed great diversity in the treatment regimens used to manage MM in real-life practice. This diversity was linked to factors such as novel agent accessibility and evolving treatment recommendations. Our results provide insight into associated clinical benefits.publishersversionPeer reviewe

A global action agenda for turning the tide on fatty liver disease

Background and Aims: Fatty liver disease is a major public health threat due to its very high prevalence and related morbidity and mortality. Focused and dedicated interventions are urgently needed to target disease prevention, treatment, and care. Approach and Results: We developed an aligned, prioritized action agenda for the global fatty liver disease community of practice. Following a Delphi methodology over 2 rounds, a large panel (R1 n = 344, R2 n = 288) reviewed the action priorities using Qualtrics XM, indicating agreement using a 4-point Likert-scale and providing written feedback. Priorities were revised between rounds, and in R2, panelists also ranked the priorities within 6 domains: epidemiology, treatment and care, models of care, education and awareness, patient and community perspectives, and leadership and public health policy. The consensus fatty liver disease action agenda encompasses 29 priorities. In R2, the mean percentage of “agree” responses was 82.4%, with all individual priorities having at least a super-majority of agreement (> 66.7% “agree”). The highest-ranked action priorities included collaboration between liver specialists and primary care doctors on early diagnosis, action to address the needs of people living with multiple morbidities, and the incorporation of fatty liver disease into relevant non-communicable disease strategies and guidance. Conclusions: This consensus-driven multidisciplinary fatty liver disease action agenda developed by care providers, clinical researchers, and public health and policy experts provides a path to reduce the prevalence of fatty liver disease and improve health outcomes. To implement this agenda, concerted efforts will be needed at the global, regional, and national levels.publishedVersio

The effect of body weight and psychological characteristics on periodontal disease development

Aim: The aim of the study was to examine the association between periodontal health in young patients with various body mass indexes and psychological traits such as temperament, level of anxiety, and autonomic nervous system tone. Materials and methods: The study included 132 male and female subjects aged 18–22 years with different body mass indexes (BMI). They were allocated into four groups by their BMIs: normal weight, overweight, and first- and second-degree obesity. We completed periodontal charts for all patients and evaluated basic oral hygiene and periodontal indexes, such as the Green-Vermillion index (OHI), the approximal plaque index by Lange (API), and papilla bleeding index by Saxer & Mühlemann (PBI). Eysenck personality questionnaire, the state-trait anxiety inventory of Spielberger-Khanin, and Wayne questionnaire were used to determine the psychological characteristics. Results: Patients with the first and second degrees of obesity were found to have the highest prevalence and severity of generalized gingivitis (up to 90%). Patients with normal BMI had significantly lower levels of extraversion and higher levels of neuroticism than the obese individuals, while subjects with extra weight and normal BMI were more emotionally stable. We found no evidence that choleric or melancholic temperament had an impact on BMI or periodontal health. However, phlegmatic temperament was found to be linked to a normal BMI, good oral hygiene, and an intact periodontium, while sanguine temperament was linked to obesity and gingivitis in young adults. A significantly higher level of state and trait anxiety was observed in obese individuals. Fifty percent of the obese subjects had disturbances of the functional state of the cardiovascular system and the tone of the autonomic nervous system. Conclusions: Because obesity and periodontal pathology are multifactorial diseases linked to lifestyle, stress tolerance, and habits, personality temperament may play a causal role in their development

Peculiarities of Alternative Fuel and Power Potential Within Aviation Transport Land Management Development

The article analyses peculiarities and specific features of the use of alternative power and fuel capacities during its formation in the sphere of air transport land management. The following elements of the system for producing power-efficient resources comprises have been considered. It substantiates the necessity to involve the concepts of design and use of a modern power-efficient airport infrastructure and its connection with sound and efficient land management. The authors consider the experience of other countries and the perspectives of alternative power and fuel resources – the "green areas". Also It have been established that every new project of an airport or a reconstructed one, shall be focused on meeting the latest standards of minimization of the airport's impact on the environment and on the reduction of climatic changes, connected with its infrastructure and activities. Within the studies of the experts in the sphere of the aviation industry, and the members of ICAO council, it have been considered the concept of development and use of a modern, power-efficient airport infrastructure. The authors have proposed a modification of the methodological calculation of resource conservation indicators by reducing fossil fuel emissions within the airport and surrounding areas